EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

被引：2

作者：

Mease, P. J. ^{[1
,2
]}

Deodhar, A. ^{[3
]}

Van der Heijde, D. ^{[4
]}

Behrens, F. ^{[5
]}

Kivitz, A. ^{[6
]}

Lehman, T. ^{[7
]}

Wei, L. ^{[8
]}

Nys, M. ^{[9
]}

Banerjee, S. ^{[10
]}

Nowak, M. ^{[11
]}

机构：

[1] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA

[3] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA

[4] Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands

[5] Goethe Univ, Translat Med & Pharmacol ITMP, CIRI Rheumatol & Fraunhofer Inst, Frankfurt, Germany

[6] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA

[7] Bristol Myers Squibb, Rheumatol, Princeton, NJ USA

[8] Bristol Myers Squibb, Med Immunol, Princeton, NJ USA

[9] Bristol Myers Squibb, GBS Biostat, Braine Lalleud, Belgium

[10] Bristol Myers Squibb, Rheumatol & Dermatol, Princeton, NJ USA

[11] Bristol Myers Squibb, Clin R&D, Princeton, NJ USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷

关键词：

D O I：

10.1136/annrheumdis-2021-eular.2653

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0227

引用

页码：137 / 138

页数：2

共 50 条

[1] Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Mease, Philip
Deodhar, Atul
van der Heijde, Desiree
Behrens, Frank
Kivitz, Alan
Lehman, Tom
Wei, Lan
Nys, Marleen
Banerjee, Subhashis
Nowak, Miroslawa
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3798 - 3800
[2] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Mease, P. J.
Deodhar, A.
Van der Heijde, D.
Behrens, F.
Kivitz, A.
Kim, J.
Singhal, S.
Nowak, M.
Banerjee, S.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 314 - 315
[3] Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Morand, Eric
Pike, Marilyn
Merrill, Joan T.
van Vollenhoven, Ronald
Werth, Victoria P.
Hobar, Coburn
Delev, Nikolay
Shah, Vaishali
Sharkey, Brian
Wegman, Thomas
Catlett, Ian
Banerjee, Subhashis
Singhal, Shalabh
ARTHRITIS & RHEUMATOLOGY, 2023, 75 (02) : 242 - 252
[4] Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
Kivitz, Alan
Muensterman, Elena Tomaselli
Kavanaugh, Arthur
van der Heijde, Desiree
Klimiuk, Piotr A.
Valenzuela, Guillermo
Dokoupilova, Eva
Poirier, Gabrielle
Srivastava, Bhaskar
Dasen, Sue
Zhang, Xinyan
Trivedi, Mona
Weng, Haoling Holly
Hong, Ting
Pothula, Peter
Baraliakos, Xenofon
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 5216 - 5219
[5] Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
Catlett, Ian M.
Gao, Lu
Hu, Yanhua
Banerjee, Subhashis
Krueger, James G.
DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2827 - 2839
[6] DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Werth, V. P.
Merola, J. F.
Wenzel, J.
Delev, N.
Kothari, H.
Meier, R.
Singhal, S.
Madireddi, M.
Korish, S.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1506 - 1506
[7] Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Pike, Marilyn
Merrill, Joan
Morand, Eric
van Vollenhoven, Ronald
Werth, Victoria
Hobar, Coburn
Delev, Nikolay
Shah, Vaishali
Sharkey, Brian
Wegman, Thomas
Catlett, Ian M.
Banerjee, Subhashis
Singhal, Shalabh
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2219 - 2221
[8] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Morand, E.
Pike, M.
Merrill, J. T.
Van Vollenhoven, R.
Werth, V. P.
Hobar, C.
Delev, N.
Shah, V.
Sharkey, B.
Wegman, T.
Catlett, I.
Banerjee, S.
Singhal, S.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 209 - 209
[9] EFFICACY OF THE ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA)
Gottlieb, Alice B.
Armstrong, April W.
Merola, Joseph F.
Napoli, Andrew
Nowak, Miroslawa
Banerjee, Subhashis
Lehman, Thomas
Mease, Philip J.
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[10] Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
Zou, Hejian
Wan, Weiguo
Xue, Yu
Sun, Lingyun
Zhang, Ning
Chen, Haiying
Shi, Xiaofei
Liu, Shengyun
Chen, Lin
Ma, Xinmei
Wei, Hua
Jiang, Zhenyu
Li, Xiaomei
Fan, Hongtao
Li, Hongbin
Li, Jingyang
Wu, Rui
Shi, Guixiu
Zhu, Jing
Kong, Xiaodan
Lu, Yuewu
Cui, Xiaojing
Zheng, Qianning
Bai, Xiaoyan
Dong, Guangchao
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5240 - 5242

← 1 2 3 4 5 →